Logo do repositório
 
Publicação

Aspirin for primary cardiovascular prevention in patients with family history of cardiovascular disease : meta-analysis

dc.contributor.authorAntunes, Miguel M.
dc.contributor.authorAlves, Mariana
dc.contributor.authorFerreira, Joaquim J
dc.contributor.authorPinto, Fausto J.
dc.contributor.authorCaldeira, Daniel
dc.date.accessioned2020-10-23T12:51:52Z
dc.date.available2020-10-23T12:51:52Z
dc.date.issued2020
dc.description© 2020 Springer Nature Switzerland AG. Part of Springer Nature.pt_PT
dc.description.abstractThe use of aspirin, while well established in the secondary prevention of cardiovascular events, remains controversial in the primary prevention of these events in the general adult population. In this setting, aspirin showed a significant but modest decrease of cardiovascular event incidence at the cost of a significantly increased risk of bleeding, a pattern that is also seen in higher risk patients, such as diabetics. It becomes exceedingly important to identify other patient clusters that would benefit from cardiovascular risk reduction at the best benefit/risk ratio.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationCardiovasc Drugs Ther (2020).pt_PT
dc.identifier.doi10.1007/s10557-020-07093-8pt_PT
dc.identifier.eissn1573-7241
dc.identifier.issn0920-3206
dc.identifier.urihttp://hdl.handle.net/10451/44647
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSpringer Naturept_PT
dc.relation.publisherversionhttps://www.springer.com/journal/10557/pt_PT
dc.titleAspirin for primary cardiovascular prevention in patients with family history of cardiovascular disease : meta-analysispt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleCardiovascular Drugs and Therapypt_PT
person.familyNameAlves
person.familyNameFerreira
person.familyNamePinto
person.familyNameCaldeira
person.givenNameMariana
person.givenNameJoaquim J
person.givenNameFausto J.
person.givenNameDaniel
person.identifier1153684
person.identifier1624753
person.identifier1308889
person.identifier.ciencia-id0718-09A9-D4EA
person.identifier.ciencia-id7D15-5CD6-6159
person.identifier.ciencia-idC311-AEDD-6DBB
person.identifier.ciencia-idAA19-EC35-8D01
person.identifier.orcid0000-0002-1369-8423
person.identifier.orcid0000-0003-3950-5113
person.identifier.orcid0000-0002-8034-4529
person.identifier.orcid0000-0002-2520-5673
person.identifier.ridO-3034-2016
person.identifier.ridG-9363-2015
person.identifier.scopus-author-id56591535500
person.identifier.scopus-author-id7403252466
person.identifier.scopus-author-id7102740158
person.identifier.scopus-author-id36623384200
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication6fd2983b-8b7d-452d-b03b-999007533ee0
relation.isAuthorOfPublication54d84fe7-2cbd-4ddc-bce2-0ff2bd7c4cc9
relation.isAuthorOfPublication5f44176f-69f5-482c-83cd-ab94425a6ec3
relation.isAuthorOfPublicationeba36bb8-5eb3-4ccc-88f8-bd7012d42382
relation.isAuthorOfPublication.latestForDiscovery6fd2983b-8b7d-452d-b03b-999007533ee0

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
Aspirin_Primary_Cardiovascular.pdf
Tamanho:
397.58 KB
Formato:
Adobe Portable Document Format